Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure

BACKGROUND: Anthracyclines are widely used in the treatment of childhood cancer. One of the well-recognized side-effects of anthracycline therapy is dose-dependent cardiomyopathy that may progress to heart failure (HF) years after completion of cancer-directed therapy. This study will evaluate the e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cardiovasc Disord
Autori principali: Armenian, Saro H., Hudson, Melissa M., Chen, Ming Hui, Colan, Steven D., Lindenfeld, Lanie, Mills, George, Siyahian, Aida, Gelehrter, Sarah, Dang, Ha, Hein, Wendy, Green, Daniel M., Robison, Leslie L., Wong, F. Lennie, Douglas, Pamela S., Bhatia, Smita
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2016
Soggetti:
Study Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5050602/
https://ncbi.nlm.nih.gov/pubmed/27716152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-016-0364-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi